Antiretroviral therapy: dolutegravir sets SAIL(ING)

被引：4
|
作者：
Boyd, Mark A. [1 ]
Donovan, Basil [1 ]
机构：
[1] Univ New S Wales, Kirby Inst Infect & Immun Soc, Sydney, NSW 2052, Australia
来源：
LANCET | 2013年 / 382卷 / 9893期
关键词：
CO-FORMULATED ELVITEGRAVIR; HIV-1; INFECTION; DOUBLE-BLIND; INITIAL TREATMENT; CONTROLLED-TRIAL; RALTEGRAVIR; EMTRICITABINE; COBICISTAT; TENOFOVIR; EFAVIRENZ;
D O I：
10.1016/S0140-6736(13)61456-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：664 / 666
页数：3
相关论文
共 50 条
  • [41] Synthesis of two diastereomeric impurities of a fluorinated antiretroviral drug dolutegravir
    Garrepalli, Sailaja
    Gudipati, Ramesh
    Amasa, Srinivasulu Reddy
    Ravindhranath, Kunta
    Pal, Manojit
    JOURNAL OF MOLECULAR STRUCTURE, 2022, 1253
  • [42] Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy
    Lu, Haidong
    Cole, Stephen R.
    Westreich, Daniel
    Hudgens, Michael G.
    Adimora, Adaora A.
    Althoff, Keri N.
    Silverberg, Michael J.
    Buchacz, Kate
    Li, Jun
    Edwards, Jessie K.
    Rebeiro, Peter F.
    Lima, Viviane D.
    Marconi, Vincent C.
    Sterling, Timothy R.
    Horberg, Michael A.
    Gill, M. John
    Kitahata, Mari M.
    Eron, Joseph J.
    Moore, Richard D.
    AIDS, 2022, 36 (02) : 277 - 286
  • [43] Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen
    Keene, Claire M.
    Griesel, Rulan
    Zhao, Ying
    Gcwabe, Zimasa
    Sayed, Kaneez
    Hill, Andrew
    Cassidy, Tali
    Ngwenya, Olina
    Jackson, Amanda
    van Zyl, Gert
    Schutz, Charlotte
    Goliath, Rene
    Flowers, Tracy
    Goemaere, Eric
    Wiesner, Lubbe
    Simmons, Bryony
    Maartens, Gary
    Meintjes, Graeme
    AIDS, 2021, 35 (09) : 1423 - 1432
  • [44] Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy
    Andreatta, Kristen
    Sax, Paul E.
    Wohl, David
    D'Antoni, Michelle L.
    Liu, Hui
    Hindman, Jason T.
    Callebaut, Christian
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, : 281 - 291
  • [45] Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy
    Kouamou, Vinie
    Manasa, Justen
    Katzenstein, David
    McGregor, Alan M.
    Ndhlovu, Chiratidzo E.
    Makadzange, Azure T.
    AIDS, 2019, 33 (11) : 1729 - 1737
  • [46] Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interaction
    Cattaneo, Dario
    Rizzardini, Giuliano
    Gervasoni, Cristina
    AIDS, 2017, 31 (06) : 867 - 868
  • [47] Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection
    Hester, E. Kelly
    Astle, Kevin
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (08) : 860 - 866
  • [48] Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States
    Walensky, Rochelle P.
    Sax, Paul E.
    Nakamura, Yoriko M.
    Weinstein, Milton C.
    Pei, Pamela P.
    Freedberg, Kenneth A.
    Paltiel, A. David
    Schackman, Bruce R.
    ANNALS OF INTERNAL MEDICINE, 2013, 158 (02) : 84 - +
  • [49] Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy
    Hsu, Jen-Yu
    Sun, Hsin-Yun
    Hsieh, Tan-Wen
    Chang, Sui-Yuan
    Chuang, Yu-Chung
    Huang, Yu-Shan
    Hsiao, Ching-Yu
    Su, Yi-Ching
    Liu, Wen-Chun
    Chang, Shu-Fang
    Hung, Chien-Ching
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2022, 29 : 7 - 16
  • [50] Perspectives on the Barrier to Resistance for Dolutegravir plus Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
    Boffito, Marta
    Waters, Laura
    Cahn, Pedro
    Paredes, Roger
    Koteff, Justin
    Van Wyk, Jean
    Vincent, Tia
    Demarest, James
    Adkison, Kimberly
    Quercia, Romina
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2020, 36 (01) : 13 - 18
12345